The company was founded in 2008 as a start-up, having about 60 employees today. Now it is a clinical stage pharmaceutical company focused on developing, manufacture and commercializing novel, locally administered therapies. It widely uses its own innovative transformational encapsulation technology. The company leading clinical stage product is a secured antibiotic reservoir. It provides and effective and safe antibacterial means to prevent and eliminate the pathogen generators in the target area by administering drugs during the process of surgical cut closure at the completion of the surgical procedure. After the surgery, the reservoir releases the antibiotics for several weeks, thus allowing prolonged treatment and prevention of infection. The technology applications overcome disadvantages of systemic treatment. The impact is highly effective despite use of only a fraction of the drug dose required in systemic approach for similar periods. Using low, but effective, dose minimizes potential side-effects and cost of treatment. The localized medication is essential in many localized medical conditions such as infections, inflammation, pain and certain cancers. Moreover, the local drug delivery overcomes systemic penetration challenges in such applications as bone, brain etc. The resulting, already developed, local treatments via encapsulated agents might be used in oncology, inflammation, pain relief, infection and bone growth. The active products are obtained by unique innovative platform designed for approved or innovative medicines. In the body they are delivered locally, at predetermined release rates and durations, over periods from days to several months. So, the application has potential to improve patient outcomes and lower the overall cost of treatment. It enables customizable, controlled and extended local delivery of drugs, thereby addressing many shortcomings of systemic administration and existing localized delivery systems. In fact, the product is based on small particles, coated by the developed multilayer matrix formulation containing the drug. The drug release occurs when the top layer comes into contact with liquid and dissolves. Duration of release is constant and prolonged as every time the upper layer dissolves while the layers below remain dry. The number of layers defines duration of the release. The drug could be inserted or injected directly at target site.
The formulation is suitable for any drug type. Duration of drug release can be adjusted by need, even for longer periods, of a month or more. The technology may represent a paradigm shift in the treatment of several localized medical conditions, including infection, pain, inflammation and cancer. At present, the company is focusing with its lead product for prevention of infection following heart surgery. There is currently no local treatment for infection prevention after open heart surgery. The only treatment available is an antibiotic injection half an hour before surgery.
The company is currently building its production capacities. The company's products are manufactured in clean rooms at the highest sterility level. The company has an office in the US aimed to support clinical trials there and starts locating the markets to enter after product receives approval. The company seeks commercial agency / distribution and services agreement with those specializing in medical aspects / drug development and know the local pharma and other companies as the following: 1. Both pharmaceutical and drug development companies who have developed a pharmaceutical molecule and need a delivery system for their drug. 2. Large pharmaceutical companies, with an emphasis on R&D contacts. The purpose - cooperation and participation in funding projects for drug delivery of various therapeutic indications. 3. Marketers / distributors for the company lead product to manage surgical site infection. 4. Medical centers for clinical trials of products